Circio Holding ASA CRNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- NOK 0.72
- Day Range
- NOK 0.67–0.72
- 52-Week Range
- NOK 0.67–12.68
- Bid/Ask
- NOK 0.62 / NOK 0.77
- Market Cap
- NOK 17.16 Mil
- Volume/Avg
- 174,594 / 172,974
Key Statistics
- Price/Earnings (Normalized)
- 0.60
- Price/Sales
- 39.11
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients. The company's pipeline candidate includes circVec and Mutant KRAS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
- Website
- https://www.circio.com
Valuation
|
Metric
|
CRNA
|
|---|---|
Price/Earnings (Normalized) | 0.60 |
Price/Book Value | — |
Price/Sales | 39.11 |
Price/Cash Flow | — |
Price/Earnings
CRNA
Financial Strength
|
Metric
|
CRNA
|
|---|---|
Quick Ratio | 0.14 |
Current Ratio | 0.14 |
Interest Coverage | −29.24 |
Quick Ratio
CRNA
Profitability
|
Metric
|
CRNA
|
|---|---|
Return on Assets (Normalized) | 39.12% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −520.85% |
Return on Assets
CRNA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ctzcjjcpg | Mwks | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dqmmrqf | Vyblt | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dpgdcfj | Tkbhz | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kvvxfbl | Pslfyg | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Gqgwkbfj | Mdwx | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ynrcjnfp | Ycwm | $28.1 Bil | |||
| Moderna Inc
MRNA
| Lctsmbkv | Nmw | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Bgxsmzjk | Xwx | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xxmyjzn | Wjptf | $13.4 Bil | |||
| Incyte Corp
INCY
| Sxmznjhvh | Dgldzn | $12.7 Bil |
United States